financetom
Business
financetom
/
Business
/
Securities Appellate Tribunal to continue hearing Punit Goenka Vs SEBI matter today
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Securities Appellate Tribunal to continue hearing Punit Goenka Vs SEBI matter today
Sep 14, 2023 7:21 AM

The Securities Appellate Tribunal (SAT) will on September 14 hear the matter related to Punit Goenka, who has been barred by the market regulator from holding key positions within four Zee group firms and in the merged entity of ZEEL and Sony Pictures Networks India.

Share Market Live

NSE

The hearing will begin at 4:30 pm.

In the last hearing on September 8, Zee’s former promoter Punit Goenka’s counsel requested SAT to set aside the Securities and Exchange Board of India's (SEBI) confirmatory order against Goenka. “The concept of keeping Punit Goenka out of office till investigation is wrong,” the counsel said.

This came after the tribunal on August 30 said it was not satisfied with eight months’ time that the markets regulator has taken for investigation.

Goenka had then argued that the former Zee promoter’s appointment as MD in Zee-Sony merged entity is not detrimental to public shareholders and that SEBI is keeping Goenka out of office for a very long time. SEBI order against Goenka is disproportionate, his counsel said and sought interim protection against it as it is premature.

SEBI is taking eight months just for investigation, it will take further time to adjudicate, the counsel pointed out. Goenka also asserted that all transactions between Zee Ent and other Essel entities have a valid basis and that the business relationship between Zee Ent and other entities in question is very old and continuous.

Additionally the markets regulator on September 13, argued before the SAT that it sees significant red flags in the transactions between Zee and Essel entities. The markets regulator argued that Zee must present evidence to show that its transactions with Essel entities were genuine and that seven Essel entities in question in the case are controlled by Zee Entertainment's Key Managerial Personnel (KMPs).

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Future Pak Confirms Proposal To Acquire Vanda Pharmaceuticals For $7.25 To $7.75 Per Share In Cash
BRIEF-Future Pak Confirms Proposal To Acquire Vanda Pharmaceuticals For $7.25 To $7.75 Per Share In Cash
Apr 17, 2024
April 17 (Reuters) - Vanda Pharmaceuticals Inc ( VNDA ): * FUTURE PAK CONFIRMS PROPOSAL TO ACQUIRE VANDA PHARMACEUTICALS FOR $7.25 TO $7.75 PER SHARE IN CASH * FUTURE PAK - PROPOSES TO ACQUIRE 100% OF ISSUED AND OUTSTANDING SHARES OF VANDA * FUTURE PAK LLC : WOULD NOT REQUIRE A FINANCING CONTINGENCY IN CONNECTION WITH A TRANSACTION * FUTURE...
Activist investor Engine Capital supports call for strategic review at Parkland
Activist investor Engine Capital supports call for strategic review at Parkland
Apr 17, 2024
April 17 (Reuters) - Activist investor Engine Capital said on Wednesday that it supports largest shareholder Simpson Oil's call for a strategic-option review at Parkland Corp ( PKIUF ) , including a sale. (Reporting by Seher Dareen in Bengaluru; Editing by Anil D'Silva) ...
What's Going On With VinFast Shares After Reaffirming Outlook Of 100,000 EV Deliveries?
What's Going On With VinFast Shares After Reaffirming Outlook Of 100,000 EV Deliveries?
Apr 17, 2024
VinFast Auto Ltd. ( VFS ) reported first-quarter earnings per share of $(0.26) loss, wider than the street view of $(0.22) loss.  EV deliveries were 9,689 in the first quarter, representing an increase of 444% year over year and a decrease of 28% from the fourth quarter of 2023. Total revenues were $302.6 million (consensus $450.618 million) in the first quarter, representing an increase of...
Abbott beats quarterly profit estimates on strong medical device sales
Abbott beats quarterly profit estimates on strong medical device sales
Apr 17, 2024
(Reuters) -Abbott Laboratories ( ABT ) beat Wall Street estimates for quarterly profit on Wednesday and raised the lower end of its annual forecast on robust sales of its medical devices, including glucose-monitoring products. Sales of Abbott's medical devices have been strengthened in recent quarters due to a resurgence in the demand for joint replacements as well as other surgeries...
Copyright 2023-2026 - www.financetom.com All Rights Reserved